- Clinical Trials
- July 2022
- 60 Pages
Global
From €1188EUR$1,250USD£1,016GBP
- Drug Pipelines
- March 2022
- 60 Pages
Global
From €1426EUR$1,500USD£1,219GBP
- Clinical Trials
- May 2021
Global
From €1426EUR$1,500USD£1,219GBP
- Drug Pipelines
- June 2020
- 68 Pages
Global
From €1901EUR$2,000USD£1,626GBP
- Report
- February 2022
- 40 Pages
India
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Saudi Arabia
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 100 Pages
Global
From €4558EUR$4,795USD£3,898GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$3,944USD£3,098GBP
- Report
- November 2022
- 40 Pages
Global
From €1901EUR$2,000USD£1,626GBP
- Report
- September 2022
- 159 Pages
Global
From €1901EUR$2,000USD£1,626GBP
- Drug Pipelines
- November 2020
- 104 Pages
Global
From €1901EUR$2,000USD£1,626GBP
- Report
- February 2022
- 40 Pages
Brazil
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
China
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
France
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Germany
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Ireland
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Japan
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Russia
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
South Korea
From €2467EUR$2,595USD£2,110GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €2467EUR$2,595USD£2,110GBP
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the nervous system and adrenal glands. It is caused by a mutation in the ABCD1 gene, which is responsible for the production of a protein that helps break down very long-chain fatty acids. Symptoms of ALD include progressive neurological deterioration, seizures, and adrenal insufficiency. Treatment for ALD is limited to supportive care and dietary management.
The Adrenoleukodystrophy Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, with a focus on developing treatments for ALD. Currently, there are no approved drugs for ALD, but several companies are researching potential therapies. These include gene therapy, enzyme replacement therapy, and stem cell therapy.
Companies in the Adrenoleukodystrophy Drug market include Sanofi, Pfizer, and Sangamo Therapeutics. Sanofi is researching gene therapy for ALD, while Pfizer is developing an enzyme replacement therapy. Sangamo Therapeutics is researching a stem cell therapy for ALD. Show Less Read more